[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 538,037,056
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.26
  • Price/Sales 5.76
  • Price/Cash Flow 15.96
  • Price/Book 6.68

Options Overview Details

View History
  • Implied Volatility 24.73% (+0.96%)
  • Historical Volatility 19.06%
  • IV Percentile 88%
  • IV Rank 70.45%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 3) 4.25 (1.91%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 12,860
  • Volume Avg (30-Day) 21,947
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 346,935
  • Open Int (30-Day) 346,463
  • Expected Range 218.84 to 227.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 8
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.37 +1.30%
on 05/11/26
235.49 -5.21%
on 05/22/26
-3.96 (-1.75%)
since 05/01/26
3-Month
220.37 +1.30%
on 05/11/26
247.88 -9.95%
on 03/03/26
-25.33 (-10.19%)
since 03/02/26
52-Week
149.04 +49.78%
on 06/20/25
251.71 -11.32%
on 03/02/26
+67.83 (+43.65%)
since 06/02/25

Most Recent Stories

More News
3 Dividend Kings That Earn Their Crown Every Quarter

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

JNJ : 223.16 (-0.16%)
BDX : 143.51 (-1.25%)
KVUE : 17.27 (-0.46%)
PEP : 141.74 (+0.16%)
RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

CHICAGO , May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj...

JNJ : 223.16 (-0.16%)
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

CHICAGO , May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus...

JNJ : 223.16 (-0.16%)
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT ® (amivantamab-vmjw)...

JNJ : 223.16 (-0.16%)
Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target

Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options...

BSX : 48.14 (+0.33%)
JNJ : 223.16 (-0.16%)
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

XLV : 146.22 (-1.10%)
JNJ : 223.16 (-0.16%)
ABBV : 212.49 (-0.21%)
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically...

JNJ : 223.16 (-0.16%)
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis

JNJ : 223.16 (-0.16%)
3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose

The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that...

KO : 78.44 (-0.25%)
PG : 139.42 (-0.61%)
JNJ : 223.16 (-0.16%)
Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

$NASX : 27,123.29 (+0.13%)
JNJ : 223.16 (-0.16%)
LLY : 1,067.92 (-1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 228.62
2nd Resistance Point 226.53
1st Resistance Point 225.02
Last Price 223.16
1st Support Level 221.42
2nd Support Level 219.33
3rd Support Level 217.82

See More

52-Week High 251.71
Last Price 223.16
Fibonacci 61.8% 212.49
Fibonacci 50% 200.38
Fibonacci 38.2% 188.26
52-Week Low 149.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.